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Background
Diabetes mellitus is a global health crisis with an 
 estimated 174 million people undiagnosed [1]. More than 
80% of these unrecognized cases occur in low- and mid-
dle-income countries (LMICs) [2]. In addition to blood glu-
cose measurements, one of the methods for diagnosing 
and managing diabetes is to analyze glycated hemoglobin 
(HbA1c) using laboratory-based instruments such as high-
performance liquid chromatography (HPLC). HbA1c is an 
ideal biomarker for monitoring diabetes treatment as it 
indicates glycemic control from the previous three to four 
months and, unlike glucose tests, does not require pre-
test fasting or measurements over two hours, has greater 
pre-analytical stability and less daily heterogeneity [3].
The use of HPLC to measure HbA1c in rural LMICs set-
tings is largely untenable due to economic and geographic 
barriers. Cost of sample collection, transportation, and 
processing is high, locations with appropriate labora-
tory standards are not easily accessible, and protocols 
for storage and transport of samples to central labs face 
significant challenges [4]. Point-of-care (POC) analyzers 
have been developed that allow healthcare providers to 
obtain rapid HbA1c results on-site with significantly fewer 
logistical challenges as the HPLC method. POC results 
are often used to supplement clinical laboratory testing, 
but there is increasing interest to use them for screening 
as well as diagnostic and therapeutic monitoring [5]. In 
clinical laboratory settings, some POC analyzers have been 
shown to perform as well as laboratory-based methods 
[6]. However, questions remain as to how accurate they 
perform in different environments, particularly in LMIC 
settings where environmental conditions are less control-
lable than a clinical laboratory.
The Afinion™ AS100 Analyzer (Alere Technologies) 
and DCA Vantage™ Analyzer (Siemens Medical 
Solutions Diagnostics) are National Glycohemoglobin 
Standardization Program (NGSP) certified POC devices 
for evaluating HbA1c [7]. Both devices have shown low 
rates of bias and imprecision from standardized test-
ing by the College of American Pathologists (CAP) [8]. 
Although healthcare providers in LMICs have recognized 
their potential for clinical use in low-income settings, very 
little is known about diabetes POC device performance 
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Assessment of Two Diabetes Point-of-care Analyzers 
Measuring Hemoglobin A1c in the Peruvian Amazon
Anthony T. Saxton*,†, J. Jaime Miranda‡,§, Ernesto J. Ortiz* and William Pan*,‖
Background: With an estimated 174 million undiagnosed cases of diabetes mellitus worldwide and 80% 
of them occurring in low- and middle-income countries an effective point-of-care diagnostic tool is key 
to fighting this global epidemic. Glycated hemoglobin has become a reliable biomarker for the diagnosis 
and prognosis of diabetes.
Objective: We assessed two point-of-care (POC) analyzers in multi-ethnic communities of the Amazon 
Rainforest in Peru where laboratory-based glycated hemoglobin (HbA1c) testing is not available.
Methods: 203 venous blood samples were tested for HbA1c by Afinion and DCA Vantage analyzers as well 
as a Premier Hb9210 high-performance liquid chromatography (HPLC) method as the reference standard. 
The coefficient of variation (CV) of each device was calculated to assess assay imprecision. Bland-Altman 
plots were used to assess bias. Ambient temperature, humidity, and barometric pressure were also evalu-
ated for their effect on HbA1c results using multivariate regression.
Findings: There was a wide range of HbA1c for participants based on the HPLC test: 4.4–9.0% 
(25–75 mmol/mol). The CV for the Afinion was 1.75%, and 4.01% for Vantage. The Afinion generated 
higher HbA1c results than the HPLC (mean difference = +0.56% [+6 mmol/mol]; p < 0.001), as did the 
DCA Vantage (mean difference = +0.32% [4 mmol/mol] p < 0.001). Temperature and humidity were not 
related to HbA1c; however, barometric pressure was associated with HPLC HbA1c results for the Afinion.
Conclusions: Imprecision and bias were not low enough to recommend either POC analyzer for HbA1c 
determinations in this setting.
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in these environments where operating conditions vary 
 significantly from controlled laboratory settings [9]. To our 
knowledge, no studies have investigated the performance 
of these HbA1c POC devices in multi-ethnic Amazonian 
groups or anywhere in South America. The increasing risk 
and continued undercount of diabetes in the Peruvian 
Amazon combined with economic and geographic barri-
ers to HPLC diagnostics make this area ideal for research 
to determine the potential implementation of POC analyz-
ers. The aim of this study was to evaluate the performance 
of the Afinion and DCA Vantage POC HbA1c analyzers for 
diabetes screening in an Amazonian region of Peru and 
compare the results to an NGSP-certified HPLC analyzer.
Methods
Setting
A cross-sectional study was performed in communi-
ties surrounding the Amarakaeri Communal Reserve in 
the southern Peruvian Amazon region of Madre de Dios 
(MDD). MDD is home to over 137,000 people, with sev-
eral indigenous tribes disbursed throughout the area [10]. 
Medical care is provided primarily in government-run 
health posts of variable quality and resources.
This study was embedded within the larger Amarakaeri 
Reserve cohort study, designed to evaluate the impact 
of natural resource extraction (natural gas and gold) on 
human and environmental health. The cohort study 
enrolled 1,122 households from 23 communities sur-
rounding the reserve that are affected directly and indi-
rectly by mining activities (Figure 1). This POC device 
ancillary study enrolled participants in six gold-mining 
communities in MDD: Huepetuhe, Quebrada Nueva, 
Caychihue, Setapo, Puquiri, and Quince Mil (Figure 1). 
These communities were selected based on: (1) their 
proximity to the city of Mazuco where all POC testing was 
performed; and (2) recommendations from the Regional 
Ministry of Health that these towns were believed to have 
the higher rates of diabetes than the reported 2.5% preva-
lence in the Peruvian jungle areas due to rapid urbaniza-
tion and gold mining that has introduced a western diet 
to MDD [11].
Point-of-care analyzers
The Afinion™ AS100 Analyzer (Alere Inc., Waltham, MA, 
USA) is a POC device that utilizes boronate affinity chro-
matography to measure the total percentage of glycation 
using a 1.5 μL sample of blood [12]. It has a reported 
HbA1c range of 4.0–15.0% and produces results in three 
minutes. Operating conditions are between 15–32°C 
(59–89°F) with 10–90% humidity for the analyzer, and 
18–30°C (64–86°F) for the test cartridge [12, 13].
The DCA Vantage™ Analyzer (Siemens Medical 
Solutions Diagnostics, Tarrytown, NY, USA) uses an immu-
noassay based on antibodies binding to glycated hemo-
globin tetrapeptide or hexapeptide molecules using a 
1.0 μL sample of blood [5]. It has a reported HbA1c range 
of 2.5%–14.0% and produces results in six minutes [14]. 
Operating conditions are between 15–40°C (61–104°F) 
with 15–90% relative humidity [14]. Both instruments 
utilize reagent cartridges that are used to collect samples 
of either capillary or venous blood and are inserted in the 
device for analysis.
Sample design
Households with at least one woman of child-bearing age 
(15–49 years) were eligible for selection in this study. Com-
munity maps were obtained for Huepetuhe, Quebrada 
Nueva, and Quince Mil to draw a random sample. Since 
there were less than 75 households in Caychihue, Puquiri, 
and Setapo, each household with a woman of child-bear-
ing age was approached to participate. Selected house-
holds that met the eligibility criterion were introduced 
to the study by trained fieldworkers, and family members 
were asked if they would like to participate. If consent was 
obtained, surveys were administered and biomarker sam-
ples were collected from the mother of the sentinel fam-
ily unit, her spouse, and any children aged 12 and under. 
Venous blood samples were collected in K2 collection 
tubes containing edetic acid (EDTA) as a preservative. The 
tubes were labeled with the patient’s name, unique iden-
tifying number, and date, then placed in a Credo Cube™ 
cold box to store the samples between 2–8°C for up to ten 
days. Capillary blood samples were also drawn and anemia 
testing was performed with a HemoCue® POC device.
Point-of-care testing
Batches of venous blood samples were delivered approxi-
mately twice per week to the town of Mazuco, where 
they were tested with the Afinion and DCA Vantage 
POC analyzers. Per manufacturer recommendations, 
before commencing tests on the participant samples 
each POC analyzer was initially verified to be in proper 
working condition by testing controls purchased from 
Figure 1: Map of study sites and location where 
HbA1c values were obtained using point-of-care 
analyzers. Green triangles represent the location of 
the six communities selected for this study, and the 
black star represents the site of HbA1c analysis using 
the point-of-care analyzers.
Saxton et al: Point-of-care Hemoglobin A1c Testing in Peruvian Amazon620 
the  manufacturers. Since HbA1c measurement can be 
affected by high temperature, the heat-sensitive color 
pads on the front of each box of DCA Vantage reagents 
was checked to ensure that the maximum temperature 
limit was not exceeded during transportation and stor-
age. In addition to recording data on the HbA1c level of 
each sample, data was collected on the temperature, rela-
tive humidity, and barometric pressure of the room at the 
time of testing using the Ambient Weather WS-110 Wire-
less Weather Station. Furthermore, a single blood sample 
near the 6.5% (48 mmol/mol) diagnostic threshold for 
diabetes was measured 14 consecutive times using both 
POC devices.
Laboratory testing
After obtaining HbA1c levels from the POC analyzers, the 
samples were stored at a −20°C cold chain and shipped to 
the Medlab Laboratory in Lima, Peru, where HbA1c lev-
els were obtained using HPLC via the Premier Hb9210™ 
Analyzer (Trinity Biotech, Wicklow, Ireland). Control sam-
ples with HbA1c values of 5.5% and 11.5% were tested 
daily on the Premier Hb9210 to ensure proper calibration 
of the analyzer. All control testing measurements were 
within a 0.2% and 0.3% deviance for the 5.5% and 11.5% 
controls, respectively.
Statistical methods
The analytical objectives were to measure imprecision of 
each POC device and to compare their HbA1c results to 
those obtained from the Premier Hb9210 analyzer. HbA1c 
was reported in Diabetes Control and Complications Trial 
(DCCT) aligned units (%) and converted to International 
Federation of Clinical Chemistry (IFCC) units (mmol 
HbA1c per mol unglycated hemoglobin) using the follow-
ing master equation [15]:
IFCC (NGSP 2.15) / 0.0915 
Imprecision was evaluated from the sample of 14 repeated 
measurements using the coefficient of variation (CV), 
 calculated as:
/CV s x
where s is the sample standard deviation and x‾ is the mean 
of the duplicates. CVs were calculated with DCCT units 
using Microsoft® Excel 2011 (Microsoft Corp.). A 2% CV 
cutoff was used to categorize devices as meeting the gen-
erally accepted performance criterion for imprecision [6].
POC and HPLC results were compared by examining 
Pearson correlation coefficients from univariate regres-
sions of paired samples and paired t-tests. Bland-Altman 
plots were used for bias assessments. Univariate  regression 
was performed to test whether the bias was constant 
across the range of HbA1c concentrations.
Ambient temperature, humidity, and barometric pres-
sure were evaluated for their effect on HbA1c results. A 
multivariate regression predicting HPLC’s HbA1c with 
results from each POC device and the ambient measure-
ments was performed. Backwards selection procedures 
were used to remove non-predictive variables from the 
model. All statistical analyses were performed with STATA 
v13.1 (StataCorp LP).
Ethical considerations
Approval for this study was obtained from the Institu-
tional Review Board of the Universidad Peruana Cayetano 
Heredia. Children 12 and older provided assent, and all 
adult participants and parents of child participants pro-
vided informed consent and were advised on the research 
aims and objectives, rationale, expected benefits, and 
rights of participants.
Results
HbA1c results using the Afinion and DCA Vantage POC 
analyzers and the Premier Hb9210 HPLC analyzer were 
obtained for 203 individuals. 137 participants were 
female (72%) with an average age of 36.6 years (range 
12–75 years). Hemoglobin concentrations were obtained 
for 196 of the 203 participants, with 38 individuals 
(19.3%) having levels under 120 g/L for women and 
130 g/L for men, indicating anemia. Anemia was more 
common in women (21.4%) than men (13.7%). Data 
about malaria was available for 198 participants, and 
11 individuals (5.6%) reported being diagnosed with 
malaria in the past year.
The HbA1c values ranged from 4.4% (25 mmol/mol) 
to 9.0% (75 mmol/mol) per the HPLC analyzer (Table 1). 
Sixteen of the 203 samples tested by the Afinion reported 
an error code indicating that the blood sample had 
hemolyzed to a level that would interfere with analysis. 
No error codes were seen with the DCA Vantage or the 
HPLC method.
For the imprecision protocol, the mean HbA1c value 
from the 14 repeated measurements of a single sample 
was 6.69% (50 mmol/mol) for the Afinion, and 6.37% 
(46 mmol/mol) for the DCA Vantage. The sample stand-
ard deviation was 0.117% for the Afinion, and 0.255% for 
the DCA Vantage. The corresponding CV was lower for the 
Afinion (1.75%) than the DCA Vantage (4.01%).
The correlation of HbA1c values between the HPLC and 
POC analyzers were slightly higher for the DCA Vantage 
than Afinion. Correlation with the Afinion was 0.92, while 
correlation for the DCA Vantage was 0.93 (Figure 2a, b).
Table 1: HbA1c concentration (% DCCT units) by method.
Afinion 
(n = 187)
DCA Vantage 
(n = 203)
HPLC 
(n = 203)
Mean (standard deviation) 5.8 (0.5) 5.5 (0.5) 5.2 (0.5)
Range 5.0–9.6 4.7–9.1 4.4–9.0
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Bias relative to the HPLC test for the Afinion was +0.56% 
(+6 mmol/mol) (95% CI 0.53% to 0.59% [6 mmol/mol]), 
p-value < 0.001 by paired t test. The bias between 
the DCA Vantage and the HPLC analyzer was +0.32% 
(+4 mmol/mol) (95% CI 0.30% to 0.35% [3–4 mmol/mol]), 
p-value < 0.001. The bias observed was constant across 
the range of HbA1c concentrations for the DCA Vantage 
(p = 0.190), but not for the Afinion (p < 0.001), where bias 
increased as HbA1c levels decreased.
The Bland-Altman limits of agreement (LOA) between 
the Afinion and the HPLC analyzer were 0.16% to 0.97% 
(2 to 11 mmol/mol), indicating that an individual from 
the studied population would have an expected dif-
ference within this range (Figure 3a). The LOA for the 
DCA Vantage and the HPLC analyzer was −0.05%–0.70% 
(−1–8 mmol/mol) (Figure 3b).
Temperature ranged from 23.9–28.4°C (median 26.4°C), 
humidity ranged from 0.70–0.91% (median 0.83%), and 
barometric pressure ranged from 28.33–28.48 inHg 
(median 28.48 inHg). From the regression analysis, tem-
perature and humidity were not related to HbA1c results 
for either POC device; however, barometric pressure was 
associated with the Afinion HbA1c. A one-unit increase 
in barometric pressure was associated with a 0.342% 
(DCCT units) increase in HbA1c (95% CI 0.050–0.634%, 
p = 0.022).
Discussion
In this study we compared the bias of the Afinion and 
DCA Vantage POC analyzers with the Premier Hb9210 
HPLC analyzer to measure HbA1c for diabetes screening 
in six Amazonian communities, and also measured the 
imprecision of the POC analyzers. Despite a high correla-
tion observed between the POC analyzers and the labora-
tory-based HPLC method, a significant positive bias was 
detected for both POC analyzers. The range widths esti-
mated for the LOAs for both devices were similar, but the 
DCA Vantage range included a mean difference of 0 while 
the Afinion did not. Both POC analyzers would have cor-
rectly categorized all five participants with diabetes using 
a 6.5% HbA1c threshold. However, amongst participants 
with an HPLC-confirmed HbA1c below 6.5%, the DCA 
Vantage incorrectly categorized one person as being in 
the diabetic range and the Afinion incorrectly categorized 
four people. In practice, this may lead to unnecessary 
medicalization and create unsustainable burdens for the 
healthcare system if the POC devices were used for HbA1c 
determination.
Figure 2: Correlation between each point-of-care analyzer to the Premier Hb9210 for measuring HbA1c 
(DCCT units). Blue dots represent individual samples, the dotted red line represents the line of identity x = y, and 
the solid black line is the regression line. Abbreviations: HbA1c, hemoglobin A1c; DCCT, Diabetes Control and 
 Complications Trial.
Figure 3: Bland-Altman plot of the differences in HbA1c measurement (using DCCT units) between each 
point-of-care analyzer and the Premier Hb9210 by mean HbA1c level. Blue dots represent individual samples. 
The horizontal black lines represent the bias (mean difference between the point-of-care analyzer and the Premier 
Hb9210) and its limits of agreement. Abbreviations: HbA1c, hemoglobin A1c; LOA, DCCT, Diabetes Control and 
Complications Trial.
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Peterson et al. [16] have also reported significant biases 
for the Afinion and the DCA Vantage, and Malkani et al. 
[17] also found a significant bias for the DCA Vantage. 
However, after programming the slope and intercept from 
their regression analyses into the DCA Vantage analyzer, 
they were able to reduce the average difference in sub-
sequent testing to less than 0.2% HbA1c, and 0.0000% 
HbA1c, respectively. If POC testing is implemented in 
MDD, this could be a useful feature for the regional min-
istry of health to incorporate to harmonize the results 
between the DCA Vantage and laboratory-based instru-
ments throughout the healthcare system.
The generally accepted performance criterion for impre-
cision is an intra-laboratory CV < 2% in DCCT units (<3% 
in SI units) [6]. We found that the CV for the Afinion 
(1.75% in DCCT units) met these standards, but the DCA 
Vantage (4.01%) did not. In practice, a low CV is important 
for clinicians to determine whether changes in HbA1c 
results over time reflect clinically significant changes in 
a patient’s glycemic status. A 0.5% (5 mmol/mol) dif-
ference in HbA1c is commonly used as an indication to 
adjust therapeutic options, although ultimately a statisti-
cally significant change in the health status of the patient 
should depend on the device’s CV and the within-person 
biological variation for HbA1c [6].
A review of the literature reveals that the CV we found 
for the Afinion is consistent with values reported in other 
studies, which range from 0.5% [16] to 3.1% [5], although 
those were all conducted in high-income countries includ-
ing the Netherlands, United States of America, Norway, 
Spain, France, and South Korea. The CV that we found for 
the DCA Vantage is slightly higher than values previously 
published, which range from 1.55% [18] to 3.74% [19]. 
The direction and magnitude of the bias for these POC 
analyzers varies. The bias reported in the literature ranges 
from −1.1% [20] to 0.8% [16] (DCCT units) for Afinion and 
−0.53% [17] to 0.9% [16] for the DCA Vantage. Some stud-
ies have found that the Afinion produced lower HbA1c 
measurements than HPLC methods, [5, 6, 20–23] while 
others report higher HbA1c measurements [6, 16, 20, 
23–26]. Eight studies have demonstrated lower results 
from the DCA vantage compared to HPLC methods [5, 6, 
17, 18, 23, 25, 27, 28] and five have reported higher values 
[6, 16, 23, 26, 27]. To our knowledge, the only study to 
test the bias of the Afinion or DCA Vantage in an LMIC or 
tropical environment was performed by Wan Mohd Zin et 
al. in Malaysia [24].
For communities in the Peruvian Amazon, access to 
laboratory diagnostics for clinical care remains lacking. 
POC testing represents an opportunity for health posts to 
obtain clinical information that would otherwise be una-
vailable for patients due to financial and transportation 
constraints. Information to help diagnose and manage 
treatment for patients with diabetes will be particularly 
important in South and Central America, where it is pro-
jected that the number of people with the disease will 
increase 65% by 2040 [2]. Importantly, we found that 
nearly 1 in 5 participants in this study were anemic and 1 in 
18 self-reported a previous case of malaria in the past year, 
which will directly affect hemoglobin  concentrations and 
produce results that are unreliable for diagnostic determi-
nations using any kind of HbA1c assay. If HbA1c testing is 
introduced in the Peruvian Amazon, we recommend the 
integration of routine proficiency testing amongst clinics 
to ensure awareness of other health conditions that may 
affect HbA1c results no matter how they were obtained, 
and also to improve consistency and enhance reliability of 
the results throughout the region.
While we were able to demonstrate the bias and impre-
cision of two POC analyzers compared to an NGSP-certified 
HPLC method, we acknowledge there were a few limita-
tions with our study. First, interference from hemoglobin 
variants was not evaluated. The Afinion and DCA Vantage 
are unaffected by most common variants (HbS, HbC, HbE, 
HbD heterozygotes) but HbF levels greater than 10–15% 
can interfere with results [29]. Also, since all reagent car-
tridges were from a single lot for each analyzer, we were 
unable to test potential lot-to-lot variability, which can be 
an additional source of error in clinical use. Although we 
followed manufacturer recommendations in the storage 
of venous whole blood, the use of samples collected in-
home and processed in a central location deviates from 
routine clinical practice and might introduce error to the 
analysis. In practice, a patient would normally travel to a 
clinic for a POC assay to be performed on-site and imme-
diately after collection. Finally, there were not enough 
patients in this study around the 6.5% HbA1c diagnostic 
threshold to provide a definitive recommendation for or 
against the use of these POC devices for diagnostic pur-
poses. Since the HbA1c results were from a largely non-
diabetic sample, with only five of 203 participants having 
HbA1c levels indicative of a diabetes diagnosis, the overall 
results cannot be extrapolated to the diabetic population 
from this cohort.
In short, in settings such as hard-to-reach populations 
and indigenous groups where there is a high need to 
initiate diabetes prevention efforts, POC devices provide 
the appeal of simplicity of use and can potentially lower 
diabetes-related costs compared with laboratory-based 
methods. However, in this study we demonstrated that 
the DCA Vantage did not meet generally accepted per-
formance criteria for HbA1c measurement precision, and 
both analyzers showed a large positive bias that may lead 
to unnecessary medicalization if utilized in this setting.
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